Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility is currently unavailable.

Matthew Langer Meyerson, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Matthew Meyerson and William Hahn.
Connection Strength

4.081
  1. Telomerase activation, cellular immortalization and cancer. Ann Med. 2001 Mar; 33(2):123-9.
    View in: PubMed
    Score: 0.247
  2. Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat Commun. 2018 12 21; 9(1):5450.
    View in: PubMed
    Score: 0.212
  3. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018 10; 50(10):1381-1387.
    View in: PubMed
    Score: 0.208
  4. Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nat Genet. 2018 07; 50(7):937-943.
    View in: PubMed
    Score: 0.205
  5. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017 12 15; 358(6369):1443-1448.
    View in: PubMed
    Score: 0.197
  6. Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor. Cancer Discov. 2018 01; 8(1):108-125.
    View in: PubMed
    Score: 0.195
  7. Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discov. 2016 08; 6(8):914-29.
    View in: PubMed
    Score: 0.178
  8. Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy. Mol Cancer Res. 2016 Feb; 14(2):207-15.
    View in: PubMed
    Score: 0.171
  9. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
    View in: PubMed
    Score: 0.169
  10. Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol. 2015 Aug; 1(5):662-7.
    View in: PubMed
    Score: 0.168
  11. Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes Dev. 2013 Jan 15; 27(2):197-210.
    View in: PubMed
    Score: 0.140
  12. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012 Sep 04; 109(36):14476-81.
    View in: PubMed
    Score: 0.137
  13. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011 Dec; 1(7):608-25.
    View in: PubMed
    Score: 0.129
  14. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011 Sep 04; 43(10):964-968.
    View in: PubMed
    Score: 0.128
  15. Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov. 2011 Sep; 1(4):297-311.
    View in: PubMed
    Score: 0.128
  16. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A. 2011 Jul 26; 108(30):12372-7.
    View in: PubMed
    Score: 0.126
  17. Making sense of cancer genomic data. Genes Dev. 2011 Mar 15; 25(6):534-55.
    View in: PubMed
    Score: 0.124
  18. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009 Nov 05; 462(7269):108-12.
    View in: PubMed
    Score: 0.112
  19. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009 Nov; 41(11):1238-42.
    View in: PubMed
    Score: 0.112
  20. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 2008 Sep 25; 455(7212):547-51.
    View in: PubMed
    Score: 0.104
  21. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007 Jun 15; 129(6):1065-79.
    View in: PubMed
    Score: 0.095
  22. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005 Nov; 2(11):e313.
    View in: PubMed
    Score: 0.085
  23. FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021 Apr 29.
    View in: PubMed
    Score: 0.062
  24. Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 1999 Oct; 5(10):1164-70.
    View in: PubMed
    Score: 0.056
  25. Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight. 2018 11 02; 3(21).
    View in: PubMed
    Score: 0.052
  26. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med. 2019 01; 21(1):213-223.
    View in: PubMed
    Score: 0.051
  27. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2018 Mar 08; 4(3):e173420.
    View in: PubMed
    Score: 0.050
  28. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 11 17; 1(19):e87062.
    View in: PubMed
    Score: 0.046
  29. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell. 2015 Mar 09; 27(3):397-408.
    View in: PubMed
    Score: 0.041
  30. BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic Acids Res. 2015 Feb 18; 43(3):e19.
    View in: PubMed
    Score: 0.040
  31. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014 May; 32(5):479-84.
    View in: PubMed
    Score: 0.038
  32. Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PLoS One. 2013; 8(9):e74950.
    View in: PubMed
    Score: 0.037
  33. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012 Jan; 2(1):82-93.
    View in: PubMed
    Score: 0.032
  34. Tumor genomic profiling of FFPE samples by massively parallel sequencing. J Clin Oncol. 2011 May 20; 29(15_suppl):10502.
    View in: PubMed
    Score: 0.031
  35. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24; 471(7339):467-72.
    View in: PubMed
    Score: 0.031
  36. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011 Aug 01; 29(22):3085-96.
    View in: PubMed
    Score: 0.031
  37. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010 Sep 16; 116(11):1919-23.
    View in: PubMed
    Score: 0.029
  38. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010 Mar 16; 17(3):298-310.
    View in: PubMed
    Score: 0.029
  39. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009 Nov 18; 4(11):e7887.
    View in: PubMed
    Score: 0.028
  40. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20380-5.
    View in: PubMed
    Score: 0.026
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.